817 related articles for article (PubMed ID: 33208445)
1. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.
Uno N; Ross TM
J Virol; 2021 Jan; 95(4):. PubMed ID: 33208445
[TBL] [Abstract][Full Text] [Related]
2. A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses.
Wollner CJ; Richner M; Hassert MA; Pinto AK; Brien JD; Richner JM
J Virol; 2021 May; 95(12):. PubMed ID: 33762420
[TBL] [Abstract][Full Text] [Related]
3. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
[TBL] [Abstract][Full Text] [Related]
4. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
[TBL] [Abstract][Full Text] [Related]
5. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
[TBL] [Abstract][Full Text] [Related]
6. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY
J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922
[TBL] [Abstract][Full Text] [Related]
7. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
[TBL] [Abstract][Full Text] [Related]
8. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
[TBL] [Abstract][Full Text] [Related]
9. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
Khanam S; Pilankatta R; Khanna N; Swaminathan S
Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
[TBL] [Abstract][Full Text] [Related]
10. Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity.
Chen RE; Smith BK; Errico JM; Gordon DN; Winkler ES; VanBlargan LA; Desai C; Handley SA; Dowd KA; Amaro-Carambot E; Cardosa MJ; Sariol CA; Kallas EG; Sékaly RP; Vasilakis N; Fremont DH; Whitehead SS; Pierson TC; Diamond MS
Cell Host Microbe; 2021 Nov; 29(11):1634-1648.e5. PubMed ID: 34610295
[TBL] [Abstract][Full Text] [Related]
11. A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates.
Thoresen D; Matsuda K; Urakami A; Ngwe Tun MM; Nomura T; Moi ML; Watanabe Y; Ishikawa M; Hau TTT; Yamamoto H; Suzaki Y; Ami Y; Smith JF; Matano T; Morita K; Akahata W
J Virol; 2024 May; 98(5):e0023924. PubMed ID: 38647327
[TBL] [Abstract][Full Text] [Related]
12. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
[TBL] [Abstract][Full Text] [Related]
13. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
14. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.
Shukla R; Ramasamy V; Shanmugam RK; Ahuja R; Khanna N
Front Cell Infect Microbiol; 2020; 10():572681. PubMed ID: 33194810
[TBL] [Abstract][Full Text] [Related]
16. Japanese encephalitis virus prM-E antigen immunization conferred protection against challenge by four different serotypes of Dengue viruses in mice.
Gao N; Li J; Sheng Z; Chen H; Fan D; Wang P; An J
Appl Microbiol Biotechnol; 2019 Jun; 103(12):4977-4986. PubMed ID: 31037380
[TBL] [Abstract][Full Text] [Related]
17. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.
Tsai WY; Chen HL; Tsai JJ; Dejnirattisai W; Jumnainsong A; Mongkolsapaya J; Screaton G; Crowe JE; Wang WK
J Virol; 2018 Dec; 92(23):. PubMed ID: 30185598
[TBL] [Abstract][Full Text] [Related]
18. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope.
Metz SW; Thomas A; White L; Stoops M; Corten M; Hannemann H; de Silva AM
Virol J; 2018 Apr; 15(1):60. PubMed ID: 29609659
[TBL] [Abstract][Full Text] [Related]
19. Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.
Briggs CM; Smith KM; Piper A; Huitt E; Spears CJ; Quiles M; Ribeiro M; Thomas ME; Brown DT; Hernandez R
J Virol; 2014 Jun; 88(12):6729-42. PubMed ID: 24696467
[TBL] [Abstract][Full Text] [Related]
20. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
